Literature DB >> 32620011

Impaired Th1 Response Is Associated With Therapeutic Failure in Patients With Cutaneous Leishmaniasis Caused by Leishmania braziliensis.

Augusto M Carvalho1,2, Luiz H Guimarães3, Rúbia Costa4, Maíra G Saldanha1, Iana Prates2, Lucas P Carvalho1,2,4, Sérgio Arruda1,4, Edgar M Carvalho1,2,4.   

Abstract

BACKGROUND: Leishmania skin test (LST) evaluates the delayed type hypersensitivity to Leishmania antigens (LA) and has been used for diagnosis of cutaneous leishmaniasis (CL). In CL patients LST is usually positive but a small percentage have negative LST. The aim of this study was to determine the clinical and immunologic features and response to antimony therapy in LST-negative CL patients.
METHODS: We compare the clinical presentation, response to therapy, and immune response of CL patients with negative vs positive LST.
RESULTS: The clinical presentation was similar in both groups but LST-negative patients had a lower cure rate. In the lesions, LST-negative patients displayed less inflammation and necrosis, and higher frequency of CD8+ T cells. Mononuclear cells from LST-negative patients had a poor T helper 1 cell (Th1) response but levels of interleukin-1β (IL-1β), IL-6, IL-17, granzyme B, and metalloproteinase-9 (MMP-9) were similar to the LST-positive group upon stimulation with LA. Leishmania internalization and killing by macrophages were similar in both groups. Cure of disease was associated with restoration of Th1 response.
CONCLUSIONS: In LST-negative patients, impaired Th1 response is associated with therapeutic failure. Increased frequency of CD8+ T cells and high production of inflammatory cytokines, granzyme B, and MMP-9 contributes to immunopathology.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990 Leishmania braziliensiszzm321990 ; zzm321990 Leishmania skin test; cutaneous leishmaniasis; IFN-γ; IL-1β; TNF; Th1 immune response; inflammation

Year:  2021        PMID: 32620011      PMCID: PMC7881333          DOI: 10.1093/infdis/jiaa374

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  47 in total

1.  Up-regulation of Th1-type responses in mucosal leishmaniasis patients.

Authors:  Olívia Bacellar; Hélio Lessa; Albert Schriefer; Paulo Machado; Amélia Ribeiro de Jesus; Walderez O Dutra; Kenneth J Gollob; Edgar M Carvalho
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

2.  Serial quantitative PCR assay for detection, species discrimination, and quantification of Leishmania spp. in human samples.

Authors:  Jason L Weirather; Selma M B Jeronimo; Shalini Gautam; Shyam Sundar; Mitchell Kang; Melissa A Kurtz; Rashidul Haque; Albert Schriefer; Sinésio Talhari; Edgar M Carvalho; John E Donelson; Mary E Wilson
Journal:  J Clin Microbiol       Date:  2011-11       Impact factor: 5.948

3.  Polar and subpolar diffuse cutaneous leishmaniasis in Brazil: clinical and immunopathologic aspects.

Authors:  A Barral; J M Costa; A L Bittencourt; M Barral-Netto; E M Carvalho
Journal:  Int J Dermatol       Date:  1995-07       Impact factor: 2.736

Review 4.  The role of interferon-gamma in the treatment of visceral and diffuse cutaneous leishmaniasis.

Authors:  R Badaro; W D Johnson
Journal:  J Infect Dis       Date:  1993-03       Impact factor: 5.226

5.  Disseminated cutaneous leishmaniasis in a field clinic in Bahia, Brazil: a report of eight cases.

Authors:  J M Costa; P D Marsden; E A Llanos-Cuentas; E M Netto; E M Carvalho; A Barral; A C Rosa; C C Cuba; A V Magalhães; A C Barreto
Journal:  J Trop Med Hyg       Date:  1986-12

6.  Lymphadenopathy as the first sign of human cutaneous infection by Leishmania braziliensis.

Authors:  A Barral; J Guerreiro; G Bomfim; D Correia; M Barral-Netto; E M Carvalho
Journal:  Am J Trop Med Hyg       Date:  1995-09       Impact factor: 2.345

7.  Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru.

Authors:  Alejandro Llanos-Cuentas; Gianfranco Tulliano; Roger Araujo-Castillo; Cesar Miranda-Verastegui; Giovanna Santamaria-Castrellon; Luis Ramirez; Marcela Lazo; Simonne De Doncker; Marleen Boelaert; Jo Robays; Jean-Claude Dujardin; Jorge Arevalo; Francois Chappuis
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

8.  Interleukin 17 production among patients with American cutaneous leishmaniasis.

Authors:  Olívia Bacellar; Daniela Faria; Márcia Nascimento; Thiago M Cardoso; Kenneth J Gollob; Walderez O Dutra; Phillip Scott; Edgar M Carvalho
Journal:  J Infect Dis       Date:  2009-07-01       Impact factor: 5.226

9.  IFN-γ production to leishmania antigen supplements the leishmania skin test in identifying exposure to L. braziliensis infection.

Authors:  Daniel Schnorr; Aline C Muniz; Sara Passos; Luiz H Guimaraes; Ednaldo L Lago; Olívia Bacellar; Marshall J Glesby; Edgar M Carvalho
Journal:  PLoS Negl Trop Dis       Date:  2012-12-20

10.  Cytotoxic T cells mediate pathology and metastasis in cutaneous leishmaniasis.

Authors:  Fernanda O Novais; Lucas P Carvalho; Joel W Graff; Daniel P Beiting; Gordon Ruthel; David S Roos; Michael R Betts; Michael H Goldschmidt; Mary E Wilson; Camila I de Oliveira; Phillip Scott
Journal:  PLoS Pathog       Date:  2013-07-18       Impact factor: 6.823

View more
  3 in total

Review 1.  Host-Directed Therapies for Cutaneous Leishmaniasis.

Authors:  Fernanda O Novais; Camila Farias Amorim; Phillip Scott
Journal:  Front Immunol       Date:  2021-03-26       Impact factor: 7.561

Review 2.  Protection and Pathology in Leishmania braziliensis Infection.

Authors:  Augusto M Carvalho; Olívia Bacellar; Edgar M Carvalho
Journal:  Pathogens       Date:  2022-04-14

3.  Influence of Obesity on Clinical Manifestations and Response to Therapy in Cutaneous Leishmaniasis Caused by Leishmania braziliensis.

Authors:  Tainã Lago; Lucas P Carvalho; Mauricio Nascimento; Luiz H Guimarães; Jamile Lago; Léa Castellucci; Augusto M Carvalho; Alex Lago; Edgar M Carvalho
Journal:  Clin Infect Dis       Date:  2021-09-15       Impact factor: 9.079

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.